In recent years, inactivated Sendai virus particles (hemagglutinating virus of Japan envelope, HVJ-E) have been shown to contribute to several anti-cancer effects, such as the activation of anti-tumor immunity via anti-tumorigenic neutrophils in the tumor microenvironment [11], the suppression of murine melanoma growth by host immune response, and the down-regulation of beta-catenin expression [12]. The gene discussed is CTNNB1; the disease is neoplasm.